ProCE Banner Activity

OAK: Impact of Continued Atezolizumab Beyond PD in Pts With Advanced NSCLC

Slideset Download
Conference Coverage
Patients who remained on atezolizumab after progression of disease by RECIST continued to derive benefit.

Released: June 07, 2017

Expiration: June 06, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology